ctla4 b7 1 Search Results


mouse ctla4[biotin]:b7-1 inhibitor screening assay kit  (AMS Biotechnology)
N/A
Mouse CTLA4[Biotin]:B7-1 Inhibitor Screening Assay Kit
   Buy from Supplier
anti cd80 monoclonal antibody  (Proteintech)
96
Proteintech anti cd80 monoclonal antibody
Targeting CD47 significantly inhibited the growth of gastric cancer in Hu-PDX models. A In the Hu-PDX1 model, tumor volume was measured twice a week and presented as mean ± SD. After treatment with SIRPα-Fc for 4 weeks, tumor weight was presented. ( n = 6 for control group and n = 8 for SIRPα-Fc group, * P < 0.05, ** P < 0.01) B Each line represented the tumor volume from an independent mouse in the Hu-PDX1 model. C In the Hu-PDX2 model, tumor volume was measured twice a week and presented as mean ± SD. After treatment with SIRPα-Fc for 4 weeks, tumor weight was presented. ( n = 6 per group, * P < 0.05, ** P < 0.01). D Each line represented the tumor volume from an independent mouse in the Hu-PDX2 model. E Representative photographs of immunohistochemical staining for <t>CD80,</t> CD163, and CD8 of tumor tissue sections and the number of CD80 + , CD163 + , and CD8 + cells in each group were normalized to the control group. The value of control was set to 1.0. ( * P < 0.05, ** P < 0.01)
Anti Cd80 Monoclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ctla4+b7+1/CD80%2FB7-1+Antibody/pmc10965671-38-0-4
Average 96 stars, based on 1 article reviews
anti cd80 monoclonal antibody - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
anti cd80  (Proteintech)
92
Proteintech anti cd80
Targeting CD47 significantly inhibited the growth of gastric cancer in Hu-PDX models. A In the Hu-PDX1 model, tumor volume was measured twice a week and presented as mean ± SD. After treatment with SIRPα-Fc for 4 weeks, tumor weight was presented. ( n = 6 for control group and n = 8 for SIRPα-Fc group, * P < 0.05, ** P < 0.01) B Each line represented the tumor volume from an independent mouse in the Hu-PDX1 model. C In the Hu-PDX2 model, tumor volume was measured twice a week and presented as mean ± SD. After treatment with SIRPα-Fc for 4 weeks, tumor weight was presented. ( n = 6 per group, * P < 0.05, ** P < 0.01). D Each line represented the tumor volume from an independent mouse in the Hu-PDX2 model. E Representative photographs of immunohistochemical staining for <t>CD80,</t> CD163, and CD8 of tumor tissue sections and the number of CD80 + , CD163 + , and CD8 + cells in each group were normalized to the control group. The value of control was set to 1.0. ( * P < 0.05, ** P < 0.01)
Anti Cd80, supplied by Proteintech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ctla4+b7+1/PE+Anti-human+CD80/pmc11036887-109-9-18
Average 92 stars, based on 1 article reviews
anti cd80 - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
ctla4 b7 1  (BPS Bioscience)
92
BPS Bioscience ctla4 b7 1
Targeting CD47 significantly inhibited the growth of gastric cancer in Hu-PDX models. A In the Hu-PDX1 model, tumor volume was measured twice a week and presented as mean ± SD. After treatment with SIRPα-Fc for 4 weeks, tumor weight was presented. ( n = 6 for control group and n = 8 for SIRPα-Fc group, * P < 0.05, ** P < 0.01) B Each line represented the tumor volume from an independent mouse in the Hu-PDX1 model. C In the Hu-PDX2 model, tumor volume was measured twice a week and presented as mean ± SD. After treatment with SIRPα-Fc for 4 weeks, tumor weight was presented. ( n = 6 per group, * P < 0.05, ** P < 0.01). D Each line represented the tumor volume from an independent mouse in the Hu-PDX2 model. E Representative photographs of immunohistochemical staining for <t>CD80,</t> CD163, and CD8 of tumor tissue sections and the number of CD80 + , CD163 + , and CD8 + cells in each group were normalized to the control group. The value of control was set to 1.0. ( * P < 0.05, ** P < 0.01)
Ctla4 B7 1, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ctla4+b7+1/CTLA4%3AB7-1%5BBiotinylated%5D+Inhibitor+Screening+Assay+Kit/us12565517-401-670-675
Average 92 stars, based on 1 article reviews
ctla4 b7 1 - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
ctla  (BPS Bioscience)
90
BPS Bioscience ctla
Targeting CD47 significantly inhibited the growth of gastric cancer in Hu-PDX models. A In the Hu-PDX1 model, tumor volume was measured twice a week and presented as mean ± SD. After treatment with SIRPα-Fc for 4 weeks, tumor weight was presented. ( n = 6 for control group and n = 8 for SIRPα-Fc group, * P < 0.05, ** P < 0.01) B Each line represented the tumor volume from an independent mouse in the Hu-PDX1 model. C In the Hu-PDX2 model, tumor volume was measured twice a week and presented as mean ± SD. After treatment with SIRPα-Fc for 4 weeks, tumor weight was presented. ( n = 6 per group, * P < 0.05, ** P < 0.01). D Each line represented the tumor volume from an independent mouse in the Hu-PDX2 model. E Representative photographs of immunohistochemical staining for <t>CD80,</t> CD163, and CD8 of tumor tissue sections and the number of CD80 + , CD163 + , and CD8 + cells in each group were normalized to the control group. The value of control was set to 1.0. ( * P < 0.05, ** P < 0.01)
Ctla, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ctla4+b7+1/CTLA4+%5BBiotinylated%5D%3AB7-1+Inhibitor+Screening+Assay+Kit/pmc07674495-43-8-12
Average 90 stars, based on 1 article reviews
ctla - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
ctla4:b7-1 tr-fret assay kit  (BPS Bioscience)
N/A
The CTLA4:B7-1 TR-FRET Assay is designed to measure the inhibition of CTLA4 binding to B7-1 in a homogeneous 384 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high
   Buy from Supplier
mouse ctla4:b7-1 tr-fret assay  (BPS Bioscience)
N/A
The mouse CTLA4:B7-1 TR-FRET Assay is designed to measure the inhibition of mouse CTLA4 binding to mouse B7-1 in a homogeneous 384 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially
   Buy from Supplier
mouse ctla4[biotin]:b7-1 inhibitor screening assay kit  (BPS Bioscience)
N/A
The Mouse CTLA4[biotin]:B7-1 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of mouse CTLA4:B7-1 signaling. The key to this kit is the high sensitivity of detection of biotin-labeled mouse CTLA4 by streptavidin-HRP.
   Buy from Supplier
ctla4:b7-1[biotinylated] inhibitor screening assay kit  (AMS Biotechnology)
N/A
CTLA4:B7-1[Biotinylated] Inhibitor Screening Assay Kit
   Buy from Supplier

Image Search Results


Targeting CD47 significantly inhibited the growth of gastric cancer in Hu-PDX models. A In the Hu-PDX1 model, tumor volume was measured twice a week and presented as mean ± SD. After treatment with SIRPα-Fc for 4 weeks, tumor weight was presented. ( n = 6 for control group and n = 8 for SIRPα-Fc group, * P < 0.05, ** P < 0.01) B Each line represented the tumor volume from an independent mouse in the Hu-PDX1 model. C In the Hu-PDX2 model, tumor volume was measured twice a week and presented as mean ± SD. After treatment with SIRPα-Fc for 4 weeks, tumor weight was presented. ( n = 6 per group, * P < 0.05, ** P < 0.01). D Each line represented the tumor volume from an independent mouse in the Hu-PDX2 model. E Representative photographs of immunohistochemical staining for CD80, CD163, and CD8 of tumor tissue sections and the number of CD80 + , CD163 + , and CD8 + cells in each group were normalized to the control group. The value of control was set to 1.0. ( * P < 0.05, ** P < 0.01)

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer

doi: 10.1007/s00262-024-03667-9

Figure Lengend Snippet: Targeting CD47 significantly inhibited the growth of gastric cancer in Hu-PDX models. A In the Hu-PDX1 model, tumor volume was measured twice a week and presented as mean ± SD. After treatment with SIRPα-Fc for 4 weeks, tumor weight was presented. ( n = 6 for control group and n = 8 for SIRPα-Fc group, * P < 0.05, ** P < 0.01) B Each line represented the tumor volume from an independent mouse in the Hu-PDX1 model. C In the Hu-PDX2 model, tumor volume was measured twice a week and presented as mean ± SD. After treatment with SIRPα-Fc for 4 weeks, tumor weight was presented. ( n = 6 per group, * P < 0.05, ** P < 0.01). D Each line represented the tumor volume from an independent mouse in the Hu-PDX2 model. E Representative photographs of immunohistochemical staining for CD80, CD163, and CD8 of tumor tissue sections and the number of CD80 + , CD163 + , and CD8 + cells in each group were normalized to the control group. The value of control was set to 1.0. ( * P < 0.05, ** P < 0.01)

Article Snippet: Anti-CD80 monoclonal antibody (66,406-1-Ig, Proteintech), anti-CD163 monoclonal antibody (GB13340, Servicebio), anti-CD8 monoclonal antibody (GB12068, Servicebio), anti-CD31 monoclonal antibody (GB113151, Servicebio), VEGFA Monoclonal antibody (19,003-1-AP, Proteintech), anti-CD47 monoclonal antibody (ab218810, Abcam), carboxyfluorescein diacetate succinimidyl ester (CFDA SE) (C0051, Beyotime), PerCP anti-CD68 (333,813, BioLegend), PE anti-CD11b (101,208, BioLegend), granulocyte–macrophage colony-stimulating factor (GM-CSF) (C003, novoprotein), FITC-labeled anti-CD47 (CC2C6, BioLegend), Human Lymphocyte separation medium (7,111,011, DAKEWE).

Techniques: Control, Immunohistochemical staining, Staining

CD47 blockade combined with antiangiogenetic therapy elicited enhanced anti-tumor effect in Hu-PDX models of gastric cancer. A and B In the Hu-PDX1 model, tumor-bearing mice were treated with SIRPα-Fc and/or VEGFR1-Fc for 4 weeks, tumor volume and tumor weight were presented as mean ± SD. Each line represented the value of the tumor volume of a single mouse. C and D In the Hu-PDX2 model, tumor volume and tumor weight were presented after the same treatment in the Hu-PDX1 model. Each line represented the value of the tumor volume of a single mouse. ( n = 6 per group, * P < 0.05, ** P < 0.01). E Representative photographs of immunohistochemical staining for CD80, CD163, CD8, and CD31 of tumor tissue sections and the number of CD80 + , CD163 + , and CD8 + cells and the relative vessel density in each group were normalized to the control group. The value of control was set to 1.0. (* P < 0.05, ** P < 0.01)

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer

doi: 10.1007/s00262-024-03667-9

Figure Lengend Snippet: CD47 blockade combined with antiangiogenetic therapy elicited enhanced anti-tumor effect in Hu-PDX models of gastric cancer. A and B In the Hu-PDX1 model, tumor-bearing mice were treated with SIRPα-Fc and/or VEGFR1-Fc for 4 weeks, tumor volume and tumor weight were presented as mean ± SD. Each line represented the value of the tumor volume of a single mouse. C and D In the Hu-PDX2 model, tumor volume and tumor weight were presented after the same treatment in the Hu-PDX1 model. Each line represented the value of the tumor volume of a single mouse. ( n = 6 per group, * P < 0.05, ** P < 0.01). E Representative photographs of immunohistochemical staining for CD80, CD163, CD8, and CD31 of tumor tissue sections and the number of CD80 + , CD163 + , and CD8 + cells and the relative vessel density in each group were normalized to the control group. The value of control was set to 1.0. (* P < 0.05, ** P < 0.01)

Article Snippet: Anti-CD80 monoclonal antibody (66,406-1-Ig, Proteintech), anti-CD163 monoclonal antibody (GB13340, Servicebio), anti-CD8 monoclonal antibody (GB12068, Servicebio), anti-CD31 monoclonal antibody (GB113151, Servicebio), VEGFA Monoclonal antibody (19,003-1-AP, Proteintech), anti-CD47 monoclonal antibody (ab218810, Abcam), carboxyfluorescein diacetate succinimidyl ester (CFDA SE) (C0051, Beyotime), PerCP anti-CD68 (333,813, BioLegend), PE anti-CD11b (101,208, BioLegend), granulocyte–macrophage colony-stimulating factor (GM-CSF) (C003, novoprotein), FITC-labeled anti-CD47 (CC2C6, BioLegend), Human Lymphocyte separation medium (7,111,011, DAKEWE).

Techniques: Immunohistochemical staining, Staining, Control

Bispecific fusion protein SIRPα-VEGFR1 elicited synergetic antitumor effect and prevented gastric cancer recurrence. A and B In the Hu-PDX1 model, tumor volume and tumor weight were measured and the data was presented as mean ± SD after treatment with SIRPα-Fc plus VEGFR1-Fc, and SIRPα-VEGFR1 for 4 weeks. Each line represented the value of the tumor volume of a single mouse. C and D In the Hu-PDX2 model, tumor volume and tumor weight were measured after the same treatment in the Hu-PDX1 model. E The number of CD80 + , CD163 + , and CD8 + cells and the relative vessel density in each group were normalized to the control group. The value of control was set to 1.0. (* P < 0.05, ** P < 0.01). F In the humanized tumor recurrence model, mice were treated with control, SIRPα-Fc + VEGFR1-Fc, SIRPα-VEGFR1 for 2 weeks, and tumor volume was measured. Each line represented the value of the tumor volume of a single mouse. G Survival curves for different treatment groups. (n = 6 per group, * P < 0.05, ** P < 0.01)

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer

doi: 10.1007/s00262-024-03667-9

Figure Lengend Snippet: Bispecific fusion protein SIRPα-VEGFR1 elicited synergetic antitumor effect and prevented gastric cancer recurrence. A and B In the Hu-PDX1 model, tumor volume and tumor weight were measured and the data was presented as mean ± SD after treatment with SIRPα-Fc plus VEGFR1-Fc, and SIRPα-VEGFR1 for 4 weeks. Each line represented the value of the tumor volume of a single mouse. C and D In the Hu-PDX2 model, tumor volume and tumor weight were measured after the same treatment in the Hu-PDX1 model. E The number of CD80 + , CD163 + , and CD8 + cells and the relative vessel density in each group were normalized to the control group. The value of control was set to 1.0. (* P < 0.05, ** P < 0.01). F In the humanized tumor recurrence model, mice were treated with control, SIRPα-Fc + VEGFR1-Fc, SIRPα-VEGFR1 for 2 weeks, and tumor volume was measured. Each line represented the value of the tumor volume of a single mouse. G Survival curves for different treatment groups. (n = 6 per group, * P < 0.05, ** P < 0.01)

Article Snippet: Anti-CD80 monoclonal antibody (66,406-1-Ig, Proteintech), anti-CD163 monoclonal antibody (GB13340, Servicebio), anti-CD8 monoclonal antibody (GB12068, Servicebio), anti-CD31 monoclonal antibody (GB113151, Servicebio), VEGFA Monoclonal antibody (19,003-1-AP, Proteintech), anti-CD47 monoclonal antibody (ab218810, Abcam), carboxyfluorescein diacetate succinimidyl ester (CFDA SE) (C0051, Beyotime), PerCP anti-CD68 (333,813, BioLegend), PE anti-CD11b (101,208, BioLegend), granulocyte–macrophage colony-stimulating factor (GM-CSF) (C003, novoprotein), FITC-labeled anti-CD47 (CC2C6, BioLegend), Human Lymphocyte separation medium (7,111,011, DAKEWE).

Techniques: Control